FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3136277801> ?p ?o ?g. }

• W3136277801 endingPage "S123" @default.
• W3136277801 startingPage "S123" @default.
• W3136277801 abstract "Introduction Treatment for insomnia often includes prescription medication but some commonly prescribed insomnia drugs, such as the GABA-ergic agonist zolpidem (ZOL), are associated with safety concerns in older adults. Studies examining methods for transitioning patients between insomnia medications of different drug classes are needed. Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) that is approved in the US, Canada, and Japan for the treatment of insomnia in adults. Study E2006-A001-312 (Study 312; NCT04009577) was a pilot study designed to examine pre-planned dosing approaches for directly transitioning from ZOL (immediate [IR] or extended release [ER] formulations) to LEM (5mg [LEM5] or 10mg [LEM10]). Here we present a post hoc analysis of outcomes in subjects aged ≥60y from Study 312. Methods The design of Study 312 comprised a 3-week Screening Period (SCR; subjects continued ZOL), 2-week Titration Period (TITR), 12-week Extension Period (EXT), and 4-week Follow-up Period. Adults with insomnia who were intermittent (INT; 3-4 nights/week) or frequent (FREQ; ≥5 nights/week) users of ZOL-IR or ZOL-ER participated. Cohort 1 included INT ZOL users and subjects with one week each of INT and FREQ ZOL usage; subjects began TITR with LEM5. Cohort 2 included FREQ ZOL users who were randomized 1:1 to LEM5 (Cohort 2A) or LEM10 (Cohort 2B). Subjects who successfully transitioned to LEM could choose to enter EXT. Subjects could change LEM dose during TITR (one dose change allowed) and EXT. The primary endpoint was the proportion of subjects who transitioned to LEM at the end of TITR. Treatment-emergent adverse events (TEAEs) were assessed based on dose at time of TEAE. Results Of the 53 subjects in the Full Analysis Set (Cohort 1, n=10; Cohort 2, n=43), 30 subjects were age ≥60y (Cohort 1, n=6; Cohort 2, n=24); mean (SD) age was 67.5 (4.9) years and 76.7% were female. During SCR, 63.3% of these 30 subjects reported that waking too early was their main sleep complaint, followed by difficulty staying asleep (30.0%) and difficulty falling asleep (6.7%). Overall, 23/30 (76.7%) transitioned to LEM after TITR. In Cohort 1, 5/6 (83.3%) transitioned, with 3 ending TITR on LEM5, and 2 on LEM10. In Cohort 2A (LEM5), 7/8 (87.5%) transitioned; with 3 ending TITR on LEM5 and 4 on LEM10. In Cohort 2B (LEM10), 11/16 (68.8%) transitioned; 1 ending TITR on LEM5 and 10 on LEM10. For the 7 subjects who discontinued during TITR, 1 subject (on LEM5) opted to discontinue and 6 subjects discontinued due to treatment-emergent adverse events (TEAEs; 1 each of intentional overdose, hemiparalysis, nausea, over-sedation, paralysis, and diarrhea; 2 were on LEM5 and 4 were on LEM10 at the time of the TEAE). The hemiparalysis and paralysis were not adjudicated as cataplexy. All 23 subjects who transitioned to LEM chose to continue in EXT. One subject discontinued during EXT and 22/30 (73.3%) subjects completed the study. Based on modal dose (defined as most frequent dose taken during TITR and EXT combined) groups, median time to first dose change during EXT was 15 days and 55 days for LEM5 and LEM10, respectively. Across the study (TITR and EXT), TEAEs occurred more frequently with LEM10 than with LEM5; the most common TEAEs (in 2 or more subjects) for either LEM dose were abnormal dreams (n=4) and somnolence (n=2). All TEAEs were mild to moderate in severity. Conclusions The majority of older subjects from Study 312 successfully transitioned from INT or FREQ ZOL-IR or ZOL-ER use to LEM, and completed the study. LEM was generally well tolerated with a safety profile that was consistent with that observed in Phase 3 clinical development. Funding Eisai Inc. Treatment for insomnia often includes prescription medication but some commonly prescribed insomnia drugs, such as the GABA-ergic agonist zolpidem (ZOL), are associated with safety concerns in older adults. Studies examining methods for transitioning patients between insomnia medications of different drug classes are needed. Lemborexant (LEM) is a dual orexin receptor antagonist (DORA) that is approved in the US, Canada, and Japan for the treatment of insomnia in adults. Study E2006-A001-312 (Study 312; NCT04009577) was a pilot study designed to examine pre-planned dosing approaches for directly transitioning from ZOL (immediate [IR] or extended release [ER] formulations) to LEM (5mg [LEM5] or 10mg [LEM10]). Here we present a post hoc analysis of outcomes in subjects aged ≥60y from Study 312. The design of Study 312 comprised a 3-week Screening Period (SCR; subjects continued ZOL), 2-week Titration Period (TITR), 12-week Extension Period (EXT), and 4-week Follow-up Period. Adults with insomnia who were intermittent (INT; 3-4 nights/week) or frequent (FREQ; ≥5 nights/week) users of ZOL-IR or ZOL-ER participated. Cohort 1 included INT ZOL users and subjects with one week each of INT and FREQ ZOL usage; subjects began TITR with LEM5. Cohort 2 included FREQ ZOL users who were randomized 1:1 to LEM5 (Cohort 2A) or LEM10 (Cohort 2B). Subjects who successfully transitioned to LEM could choose to enter EXT. Subjects could change LEM dose during TITR (one dose change allowed) and EXT. The primary endpoint was the proportion of subjects who transitioned to LEM at the end of TITR. Treatment-emergent adverse events (TEAEs) were assessed based on dose at time of TEAE. Of the 53 subjects in the Full Analysis Set (Cohort 1, n=10; Cohort 2, n=43), 30 subjects were age ≥60y (Cohort 1, n=6; Cohort 2, n=24); mean (SD) age was 67.5 (4.9) years and 76.7% were female. During SCR, 63.3% of these 30 subjects reported that waking too early was their main sleep complaint, followed by difficulty staying asleep (30.0%) and difficulty falling asleep (6.7%). Overall, 23/30 (76.7%) transitioned to LEM after TITR. In Cohort 1, 5/6 (83.3%) transitioned, with 3 ending TITR on LEM5, and 2 on LEM10. In Cohort 2A (LEM5), 7/8 (87.5%) transitioned; with 3 ending TITR on LEM5 and 4 on LEM10. In Cohort 2B (LEM10), 11/16 (68.8%) transitioned; 1 ending TITR on LEM5 and 10 on LEM10. For the 7 subjects who discontinued during TITR, 1 subject (on LEM5) opted to discontinue and 6 subjects discontinued due to treatment-emergent adverse events (TEAEs; 1 each of intentional overdose, hemiparalysis, nausea, over-sedation, paralysis, and diarrhea; 2 were on LEM5 and 4 were on LEM10 at the time of the TEAE). The hemiparalysis and paralysis were not adjudicated as cataplexy. All 23 subjects who transitioned to LEM chose to continue in EXT. One subject discontinued during EXT and 22/30 (73.3%) subjects completed the study. Based on modal dose (defined as most frequent dose taken during TITR and EXT combined) groups, median time to first dose change during EXT was 15 days and 55 days for LEM5 and LEM10, respectively. Across the study (TITR and EXT), TEAEs occurred more frequently with LEM10 than with LEM5; the most common TEAEs (in 2 or more subjects) for either LEM dose were abnormal dreams (n=4) and somnolence (n=2). All TEAEs were mild to moderate in severity. The majority of older subjects from Study 312 successfully transitioned from INT or FREQ ZOL-IR or ZOL-ER use to LEM, and completed the study. LEM was generally well tolerated with a safety profile that was consistent with that observed in Phase 3 clinical development." @default.
• W3136277801 created "2021-03-29" @default.
• W3136277801 creator A5020477271 @default.
• W3136277801 creator A5020609025 @default.
• W3136277801 creator A5038032789 @default.
• W3136277801 creator A5048780673 @default.
• W3136277801 creator A5078195357 @default.
• W3136277801 creator A5082868877 @default.
• W3136277801 date "2021-04-01" @default.
• W3136277801 modified "2023-09-25" @default.
• W3136277801 title "A Multicenter Open-label Pilot Study Evaluating Next-Dose Transition From Zolpidem to Lemborexant: Subgroup Analysis of Older Adults" @default.
• W3136277801 doi "https://doi.org/10.1016/j.jagp.2021.01.118" @default.
• W3136277801 hasPublicationYear "2021" @default.
• W3136277801 type Work @default.
• W3136277801 sameAs 3136277801 @default.
• W3136277801 citedByCount "0" @default.
• W3136277801 crossrefType "journal-article" @default.
• W3136277801 hasAuthorship W3136277801A5020477271 @default.
• W3136277801 hasAuthorship W3136277801A5020609025 @default.
• W3136277801 hasAuthorship W3136277801A5038032789 @default.
• W3136277801 hasAuthorship W3136277801A5048780673 @default.
• W3136277801 hasAuthorship W3136277801A5078195357 @default.
• W3136277801 hasAuthorship W3136277801A5082868877 @default.
• W3136277801 hasConcept C126322002 @default.
• W3136277801 hasConcept C15744967 @default.
• W3136277801 hasConcept C187960798 @default.
• W3136277801 hasConcept C2777123777 @default.
• W3136277801 hasConcept C2781210498 @default.
• W3136277801 hasConcept C71924100 @default.
• W3136277801 hasConcept C95190672 @default.
• W3136277801 hasConcept C98274493 @default.
• W3136277801 hasConceptScore W3136277801C126322002 @default.
• W3136277801 hasConceptScore W3136277801C15744967 @default.
• W3136277801 hasConceptScore W3136277801C187960798 @default.
• W3136277801 hasConceptScore W3136277801C2777123777 @default.
• W3136277801 hasConceptScore W3136277801C2781210498 @default.
• W3136277801 hasConceptScore W3136277801C71924100 @default.
• W3136277801 hasConceptScore W3136277801C95190672 @default.
• W3136277801 hasConceptScore W3136277801C98274493 @default.
• W3136277801 hasIssue "4" @default.
• W3136277801 hasLocation W31362778011 @default.
• W3136277801 hasOpenAccess W3136277801 @default.
• W3136277801 hasPrimaryLocation W31362778011 @default.
• W3136277801 hasRelatedWork W1839123200 @default.
• W3136277801 hasRelatedWork W1972130003 @default.
• W3136277801 hasRelatedWork W1998354297 @default.
• W3136277801 hasRelatedWork W2012627536 @default.
• W3136277801 hasRelatedWork W2070997142 @default.
• W3136277801 hasRelatedWork W2134141889 @default.
• W3136277801 hasRelatedWork W2241109898 @default.
• W3136277801 hasRelatedWork W2511084698 @default.
• W3136277801 hasRelatedWork W2748952813 @default.
• W3136277801 hasRelatedWork W2899084033 @default.
• W3136277801 hasVolume "29" @default.
• W3136277801 isParatext "false" @default.
• W3136277801 isRetracted "false" @default.
• W3136277801 magId "3136277801" @default.
• W3136277801 workType "article" @default.